Pre-treatment Hyponatremia as a Novel Prognostic Biomarker for Tandem CD19/CD20 CAR-T Cell Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma

In the fight against certain types of blood cancer, doctors have developed a powerful new weapon: a treatment that reprograms a patient's own immune cells to hunt down and destroy malignant tumors. This approach, known as CAR-T cell therapy, has offered hope to people whose cancer has returned or refused to respond to standard medicines. However, the path to recovery is not the same for everyone. While some patients achieve long-term remission, others do not respond at all, and the reasons for this difference have remained difficult to predict. Doctors have long looked for clues in the patient's body—such as the size of the tumor or the general strength of the immune system—to guess who will benefit most. The challenge has been finding a signal that is simple to measure, available in every hospital, and truly meaningful before the treatment even begins.

A team of researchers at the Chinese PLA General Hospital recently turned their attention to a routine blood test that is usually taken for basic health monitoring: the measurement of sodium levels. Sodium is a mineral that helps the body maintain fluid balance and nerve function. In the context of serious illness, low sodium levels often signal that the body is under significant stress, perhaps due to inflammation, poor nutrition, or the sheer burden of disease. The researchers wondered if this simple number, measured just before a patient received CAR-T therapy, could act as a warning sign. They asked whether a patient starting treatment with low sodium would face a harder road than a patient with normal levels, and if tracking sodium changes after treatment could reveal how well the therapy was working.

To find the answer, the team looked back at the records of 76 patients with relapsed or refractory non-Hodgkin lymphoma who had received a specific type of CAR-T therapy called TanCAR7. This treatment targets two markers on the cancer cells, CD19 and CD20, to ensure a more thorough attack. The researchers focused on the sodium levels recorded within a week before the patients received the lymphodepleting chemotherapy that prepares the body for the new cells. They defined low sodium as anything below 135 millimoles per liter. Among the 76 people in the study, 29 began treatment with low sodium levels, while the remaining 47 had normal levels.

The results revealed a clear divide between the two groups. Patients who started with low sodium were significantly less likely to see their cancer shrink or disappear. While nearly 90 percent of patients with normal sodium levels achieved a positive response to the therapy, only about 69 percent of those with low sodium levels did so. More concerning was the difference in how long the benefits lasted. For the group with normal sodium, the median time before the cancer returned or the patient passed away had not been reached even after more than five years of follow-up. In contrast, patients with low sodium saw their cancer return or their condition worsen much sooner, with a median survival time of just under 19 months. The risk of the cancer progressing was more than twice as high for those with low sodium, and their overall chance of survival was also significantly reduced.

These findings held true even when the researchers accounted for other factors that are known to influence outcomes, such as the patient's age, the aggressiveness of the cancer type, and their overall physical fitness. This suggests that the sodium level itself carries unique information about the patient's ability to withstand the treatment and fight the disease. It appears that low sodium is not just a random lab value but a marker of a body that is already struggling with the stress of the cancer, perhaps due to high levels of inflammation or a reduced ability to manage fluid balance.

The study also looked at what happened to sodium levels after the treatment was given. In patients who responded well to the therapy, sodium levels dipped slightly in the first week—a common reaction to the intense immune activity—but then quickly returned to normal and stayed there. However, in patients who did not respond, sodium levels dropped much deeper and failed to recover, remaining low for months. This pattern suggests that monitoring sodium after treatment could serve as a simple, ongoing check-in. If a patient's sodium levels stay low or continue to fall, it might signal that the treatment is not working or that the disease is returning, long before other symptoms appear.

The researchers emphasize that while these results are promising, they come from a single group of patients and need to be confirmed in larger studies. They do not suggest that low sodium causes the treatment to fail, but rather that it identifies a group of patients who are already in a more vulnerable state. The value of this discovery lies in its simplicity. Sodium is measured in almost every hospital, costs nothing extra, and requires no special equipment. If future studies confirm these findings, doctors could use this routine test to identify patients who might need extra support, closer monitoring, or a different approach to care before they even receive the CAR-T infusion. For now, the study offers a clear message: a simple blood test can reveal a great deal about the complex battle between a patient's body and their cancer.